Study guide
14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation
EDAIC Part I European Diploma in Anaesthesiology and Intensive Care
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The EDAIC Part I Examination
1.1 EDAIC Part I Exam Format, Scoring and Multiple True/False Strategy
2 Chapter 2: Anatomy for Anaesthesia and Intensive Care
2.1 Functional Anatomy of the Upper Airway, Larynx, and Tracheobronchial Tree 2.2 Neuraxial Anatomy: Spine, Spinal Cord, Meninges, and Spaces 2.3 Vascular Anatomy for Central and Peripheral Cannulation 2.4 Peripheral Nerve Plexuses and Autonomic Nervous System Pathways 2.5 Thoracic Anatomy: Chest Wall, Intercostal Spaces, Pleura, Mediastinum and Heart
3 Chapter 3: Respiratory and Cardiovascular Physiology
3.1 Respiratory Mechanics, Lung Volumes, and Work of Breathing 3.2 Ventilation-Perfusion Relationships, Shunt, and Gas Exchange 3.3 Control of Breathing, Hypoxia, Altitude and Hyperbaric Physiology 3.4 Cardiac Cycle, Electrophysiology, and Ventricular Function 3.5 Vascular Resistance, Microcirculation, and Systemic Hemodynamics
4 Chapter 4: Neurophysiology, Renal, Hepatic and Acid-Base Physiology
4.1 Cerebral Blood Flow, Intracranial Pressure, and CSF Dynamics 4.2 Renal Physiology, Glomerular Filtration, and Tubular Transport 4.3 Hepatic Blood Flow, Metabolism, and Clearance 4.4 Acid-Base Regulation, Buffering Systems, and Stewart Approach
5 Chapter 5: Endocrine and Haematological Physiology
5.1 Endocrine Physiology and the Neuroendocrine Stress Response 5.2 Haemostasis Physiology, Coagulation Testing and Inherited Bleeding Disorders
6 Chapter 6: Special Patient Physiology: Maternal, Paediatric and Geriatric
6.1 Maternal Physiological Adaptations to Pregnancy and Uteroplacental Flow 6.2 Neonatal and Paediatric Physiological Differences 6.3 Physiological Changes of Ageing and Thermoregulation
7 Chapter 7: General Pharmacological Principles and Inhalational Anaesthetics
7.1 Pharmacokinetic Principles, Compartmental Models, and Clearance 7.2 Pharmacodynamic Mechanisms, Receptor Theory, and Drug Interactions 7.3 Physical Properties, Uptake, and Distribution of Volatile Anaesthetics 7.4 Minimum Alveolar Concentration (MAC), Organ Effects, and Toxicity
8 Chapter 8: Intravenous Agents, Neuromuscular Blockade and Analgesics
8.1 Intravenous Induction Agents: Propofol, Etomidate, Ketamine, and Barbiturates 8.2 Neuromuscular Blocking Agents: Depolarizing and Non-Depolarizing Drugs 8.3 Neuromuscular Monitoring and Reversal: Anticholinesterases and Sugammadex 8.4 Opioid Pharmacology, Receptors, and Non-Opioid Analgesic Agents
9 Chapter 9: Cardiovascular Drugs, Autonomic Pharmacology and Local Anaesthetics
9.1 Inotropes, Vasopressors, and Inodilators in Perioperative Care 9.2 Antiarrhythmic, Antihypertensive, and Beta-Adrenergic Antagonist Drugs 9.3 Local Anaesthetic Pharmacology, Toxicity (LAST), and Lipid Emulsion Therapy
10 Chapter 10: Haematological and Internal Medicine Pharmacology
10.1 Anticoagulant, Antiplatelet and Haemostatic Drugs and Their Reversal 10.2 Internal Medicine Drugs: Endocrine, Respiratory, Psychiatric and Antiepileptic Agents and Their Anaesthetic Interactions
11 Chapter 11: Physics, Clinical Measurement and Medical Equipment
11.1 Physical Gas Laws, Fluid Dynamics, and Resistance Principles 11.2 Anaesthetic Machines, Gas Supply Pipelines, Cylinders, and Safety Mechanisms 11.3 Breathing Systems, Vaporizer Mechanics, and Scavenging Systems 11.4 Invasive and Non-Invasive Hemodynamic and Respiratory Monitoring
12 Chapter 12: Electrical Safety, Temperature, Humidity and Gas Analysis
12.1 Electricity, Electrical Safety, Diathermy, Defibrillation, Implanted Devices and Fire 12.2 Temperature Measurement, Humidity, Gas Analysis and SI Units
13 Chapter 13: Biostatistics, Clinical Trials and Evidence Appraisal
13.1 Descriptive Statistics, Distributions, and Parametric vs Non-Parametric Tests 13.2 Hypothesis Testing, Power, Type I/II Errors, and Confidence Intervals 13.3 Clinical Study Designs, Bias, and Diagnostic Test Performance (Sensitivity, Specificity, ROC)
14 Chapter 14: General Anaesthesia, Preoperative Evaluation and Airway Management
14.1 Preoperative Risk Assessment, Cardiovascular Risk Indices, and Fasting Guidelines 14.2 The Difficult Airway: Assessment, Algorithms, and Rescue Oxygenation 14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation 14.4 Post-Anaesthesia Care Unit (PACU) Management, Emergence, and Postoperative Nausea/Vomiting
15 Chapter 15: Coexisting Disease and Preoperative Investigations
15.1 Interpreting Investigations: ECG, Chest Radiograph, Lung Function and Blood Tests 15.2 Coexisting Disease I: Asthma, COPD, Obstructive Sleep Apnoea, Obesity, Liver and Renal Disease 15.3 Endocrine Disease and Emergencies: Diabetes, DKA and HHS, Thyroid, Adrenal, Phaeochromocytoma and Carcinoid 15.4 Coexisting Disease II: Neuromuscular and Neurological Disease
16 Chapter 16: Subspecialty Anaesthesia: Cardiothoracic, Vascular and Neuroanaesthesia
16.1 Anaesthesia for Cardiac Surgery and Cardiopulmonary Bypass Management 16.2 Thoracic Anaesthesia, One-Lung Ventilation, and Major Vascular Surgery 16.3 Neuroanaesthesia: Craniotomy, Sitting Position, and Traumatic Brain Injury
17 Chapter 17: Obstetric, Paediatric and Ambulatory Anaesthesia
17.1 Obstetric Analgesia and Anaesthesia: Labour, Caesarean Delivery, and High-Risk Conditions 17.2 Paediatric Anaesthesia: Induction, Airway Management, and Emergencies 17.3 Ambulatory Day-Surgery Selection, Premedication, and Elderly Patient Anaesthesia
18 Chapter 18: Anaesthetic Complications and Specialty Settings
18.1 Anaesthetic Complications: Accidental Awareness, Aspiration, Positioning Injuries, Visual Loss and Dental Damage 18.2 Anaesthesia for ENT and Laser Airway Surgery, Ophthalmic Surgery, and Laparoscopic and Robotic Surgery
19 Chapter 19: Regional Anaesthesia and Acute/Chronic Pain Management
19.1 Neuraxial Techniques: Spinal, Epidural, and Caudal Anaesthesia 19.2 Upper and Lower Limb Peripheral Nerve and Fascial Plane Blocks 19.3 Multimodal Acute Postoperative Pain Management and ERAS Pathways 19.4 Chronic and Neuropathic Pain Syndromes and Interventional Management 19.5 Palliative Symptom Control, Psychological Aspects of Pain and Multidisciplinary Pain Management
20 Chapter 20: Intensive Care Medicine: Ventilation, Shock and Organ Support
20.1 Acute Respiratory Distress Syndrome (ARDS) and Mechanical Ventilation Strategies 20.2 Sepsis-3 Definitions, Septic Shock, and Hemodynamic Resuscitation 20.3 Acute Kidney Injury, Indications for Dialysis, and Continuous Renal Replacement Therapy 20.4 ICU Sedation, Delirium, Weaning, and Brain Death Determination
21 Chapter 21: Intensive Care Medicine: Admission, Nutrition, Infection and Electrolytes
21.1 ICU Admission, Severity Scoring, Nutrition and Routine Prophylaxis 21.2 Antimicrobial Therapy, Stewardship and ICU-Acquired Infections 21.3 Electrolyte Disorders: Sodium, Potassium, Calcium, Magnesium and Phosphate
22 Chapter 22: Intensive Care and Emergency Medicine: Neurocritical Care, Poisoning and Cardiorespiratory Emergencies
22.1 Neurocritical Care: Subarachnoid Haemorrhage, Stroke, Status Epilepticus and Acute Neuromuscular Failure 22.2 Acute Poisoning: Toxidromes, Decontamination and Specific Antidotes 22.3 Acute Cardiorespiratory Emergencies: Pulmonary Embolism, Acute Severe Asthma and COPD, Non-Invasive Support and Acute Heart Failure
23 Chapter 23: Resuscitation, Perioperative Emergencies and Professional Ethics
23.1 Advanced Life Support (ALS) Guidelines and Perioperative Cardiac Arrest 23.2 Perioperative Crises: Malignant Hyperthermia and Severe Anaphylaxis 23.3 Major Trauma, Hemorrhagic Shock, and Massive Transfusion Protocols 23.4 Professional Ethics, Informed Consent, Patient Safety, and Helsinki Declaration
24 Chapter 24: Newborn, Paediatric and Obstetric Emergencies
24.1 Newborn Life Support and Paediatric Life Support 24.2 Obstetric Emergencies: Maternal Collapse, Amniotic Fluid Embolism, Uterine Inversion and Resuscitative Hysterotomy
25 Chapter 25: Burns, Environmental Emergencies and Patient Transport
25.1 Burns, Inhalation Injury, Drowning, Hypothermia, Heat Illness and Decompression Illness 25.2 Prehospital Care and Intra- and Inter-Hospital Transport of the Critically Ill
14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation
Key Takeaways Explain This Topic AI
Total Body Water (TBW) constitutes 60 % 60\% 60% of body weight in adult males and 50 % 50\% 50% in females; two-thirds is intracellular fluid ( I C F ICF I CF ) and one-third is extracellular fluid ( E C F ECF ECF ), which is partitioned into interstitial fluid ( 3 / 4 3/4 3/4 ) and intravascular plasma volume ( 1 / 4 1/4 1/4 ).
Balanced crystalloids (Hartmann's, Plasmalyte) have a physiological Strong Ion Difference ( S I D = 28 − 50 mEq/L SID = 28-50\text{ mEq/L} S I D = 28 − 50 mEq/L ) and physiological chloride concentrations; 0.9 % 0.9\% 0.9% Normal Saline has a S I D SID S I D of zero ( [ C l − ] = 154 mmol/L [Cl^-] = 154\text{ mmol/L} [ C l − ] = 154 mmol/L ) and in large volumes causes hyperchloremic metabolic acidosis and renal afferent vasoconstriction, although outcome differences in trials (SMART, BaSICS, PLUS) are small.
Synthetic colloids (hydroxyethyl starches / HES) induce acute kidney injury, increase renal replacement therapy requirements, and cause acquired coagulopathy, leading to regulatory suspensions; natural colloids (5% and 20% human albumin) remain indicated for specific volume expansion and severe hypoalbuminemia.
Dynamic parameters (Stroke Volume Variation / SVV and Pulse Pressure Variation / PPV) predict fluid responsiveness via heart-lung interactions; their validity strictly requires sinus rhythm, closed thorax, absence of spontaneous breathing efforts, and controlled mechanical ventilation with tidal volume ≥ 8 mL/kg \ge 8\text{ mL/kg} ≥ 8 mL/kg ideal body weight.
Patient Blood Management (PBM) encompasses three pillars: optimizing preoperative erythropoiesis (iron, ESA), minimizing surgical blood loss (meticulous hemostasis, tranexamic acid, cell salvage, acute normovolemic hemodilution), and employing restrictive transfusion triggers ( H b < 70 − 80 g/L Hb < 70-80\text{ g/L} H b < 70 − 80 g/L in stable patients, with a more liberal threshold near 100 g/L 100\text{ g/L} 100 g/L often used in acute myocardial infarction after the MINT trial), guided by viscoelastic testing (ROTEM/TEG).
Last updated: October 2026
14.3 Intraoperative Fluid Therapy, Goal-Directed Hemodynamics, and Blood Conservation
Intraoperative fluid management has evolved from unmonitored empirical fluid replacement toward individualized, physiology-guided therapy. Both hypovolemia and hypervolemic fluid overload cause substantial perioperative morbidity. Understanding fluid compartmental kinetics, the physical chemistry of crystalloid solutions, dynamic hemodynamic indices, and the three pillars of Patient Blood Management is essential for modern anaesthetic practice.
- 1. Physiological Fluid Compartments and the Endothelial Glycocalyx
- Fluid Compartment Anatomy
In an average adult male, Total Body Water (TBW) constitutes approximately 60 % 60\% 60% of total body weight ( 42 L 42\text{ L} 42 L in a 70 kg 70\text{ kg} 70 kg adult). In adult females, higher adipose content reduces TBW to approximately 50 % 50\% 50% ( 35 L 35\text{ L} 35 L in a 70 kg 70\text{ kg} 70 kg adult). In neonates, TBW reaches 75 − 80 % 75-80\% 75 − 80% . [ TOTAL BODY WATER (TBW) ]
- (60% of Body Weight: ~42 L)
- |
- +-----------------------------+-----------------------------+
- | |
- [ Intracellular Fluid (ICF) ] [ Extracellular Fluid (ECF) ]
- (2/3 of TBW: ~28 L / 40% BW) (1/3 of TBW: ~14 L / 20% BW)
- Major ions: K+, Mg2+, PO4(3-), Proteins Major ions: Na+, Cl-, HCO3-
- |
- +-----------------------------+-----------------------------+
- | |
- [ Interstitial Fluid (ISF) ] [ Intravascular Plasma ]
- (3/4 of ECF: ~10.5 L / 15% BW) (1/4 of ECF: ~3.5 L / 5% BW)
Intracellular Fluid ( I C F ICF I CF ): Two-thirds ( 2 / 3 2/3 2/3 ) of TBW ( ≈ 40 % \approx 40\% ≈ 40% of body weight, ≈ 28 L \approx 28\text{ L} ≈ 28 L ). High concentrations of potassium ( K + ≈ 140 − 150 mmol/L K^+ \approx 140-150\text{ mmol/L} K + ≈ 140 − 150 mmol/L ), magnesium, organic phosphates, and proteins.
Extracellular Fluid ( E C F ECF ECF ): One-third ( 1 / 3 1/3 1/3 ) of TBW ( ≈ 20 % \approx 20\% ≈ 20% of body weight, ≈ 14 L \approx 14\text{ L} ≈ 14 L ). High concentrations of sodium ( N a + ≈ 140 mmol/L Na^+ \approx 140\text{ mmol/L} N a + ≈ 140 mmol/L ) and chloride ( C l − ≈ 100 mmol/L Cl^- \approx 100\text{ mmol/L} C l − ≈ 100 mmol/L ). The E C F ECF ECF is subdivided into:
Interstitial Fluid ( I S F ISF I SF ): Three-fourths ( 3 / 4 3/4 3/4 ) of E C F ECF ECF ( ≈ 15 % \approx 15\% ≈ 15% of body weight, ≈ 10.5 L \approx 10.5\text{ L} ≈ 10.5 L ).
Intravascular Plasma Volume: One-fourth ( 1 / 4 1/4 1/4 ) of E C F ECF ECF ( ≈ 5 % \approx 5\% ≈ 5% of body weight, ≈ 3.5 L \approx 3.5\text{ L} ≈ 3.5 L ). Adding red blood cell volume ( ≈ 2.0 L \approx 2.0\text{ L} ≈ 2.0 L ) yields a total circulating blood volume of ≈ 5.0 − 5.5 L \approx 5.0-5.5\text{ L} ≈ 5.0 − 5.5 L ( 70 mL/kg 70\text{ mL/kg} 70 mL/kg in adult males, 65 mL/kg 65\text{ mL/kg} 65 mL/kg in females).
The Endothelial Glycocalyx Layer (EGL)
The revised Starling principle recognizes that transvascular fluid filtration occurs across the endothelial glycocalyx layer —a delicate, 0.5 − 1.0 μ m 0.5-1.0\text{ }\mu\text{m} 0.5 − 1.0 μ m thick meshwork of membrane-bound proteoglycans (syndecans, glypicans) and glycosaminoglycans (heparan sulfate, chondroitin sulfate, hyaluronic acid) coating the luminal surface of healthy vascular endothelium.
The glycocalyx maintains vascular barrier competence, prevents leukocyte and platelet adhesion, and restricts protein extravasation.
Disruption of the Glycocalyx: Hypervolemia (via atrial natriuretic peptide / ANP release triggered by atrial stretch), acute hyperglycemia, ischemia-reperfusion injury, sepsis, and major surgical trauma strip the glycocalyx. Once destroyed, intravenous crystalloids and colloids rapidly leak directly into the interstitial space, causing severe tissue edema, impaired microcirculatory oxygen delivery, and prolonged postoperative ileus.
2. Crystalloids versus Colloids: Electrolyte Compositions and Acid-Base Physics
Solution N a + Na^+ N a + (mmol/L) C l − Cl^- C l − (mmol/L) K + K^+ K + (mmol/L) C a 2 + Ca^{2+} C a 2 + (mmol/L) M g 2 + Mg^{2+} M g 2 + (mmol/L) Buffer (mmol/L) Osmolarity (mOsm/L) S I D SID S I D (mEq/L)
Human Plasma 135--145 98--106 3.5--5.0 2.2--2.6 0.8--1.0 H C O 3 − HCO_3^- H C O 3 − (24--28) 280--295 38--42
- 0.9% Normal Saline 154 154 0 0 0 None 308 0
- Hartmann's (Compound Sodium Lactate) 131 111 5 2 0 Lactate (29) 278 29
- Plasmalyte 148 140 98 5.0 0 1.5 Acetate (27), Gluconate (23) 294 50
5% Human Albumin 130--160 Varies by product < 2 < 2 < 2 0 0 None (octanoate stabiliser) ≈ 300 \approx 300 ≈ 300 Varies by product
Stewart Physical-Chemical Acid-Base Model & Normal Saline
Under Peter Stewart's quantitative acid-base theory, plasma [ H + ] [H^+] [ H + ] and [ H C O 3 − ] [HCO_3^-] [ H C O 3 − ] are dependent variables dictated by three independent variables:
The Strong Ion Difference ( S I D = ∑ [ Strong Cations ] − ∑ [ Strong Anions ] SID = \sum [\text{Strong Cations}] - \sum [\text{Strong Anions}] S I D = ∑ [ Strong Cations ] − ∑ [ Strong Anions ] ): S I D = ( [ N a + ] + [ K + ] + [ C a 2 + ] + [ M g 2 + ] ) − ( [ C l − ] + [ Other Strong Anions ] ) SID = ([Na^+] + [K^+] + [Ca^{2+}] + [Mg^{2+}]) - ([Cl^-] + [\text{Other Strong Anions}]) S I D = ([ N a + ] + [ K + ] + [ C a 2 + ] + [ M g 2 + ]) − ([ C l − ] + [ Other Strong Anions ]) Normal plasma S I D SID S I D is approximately 38 − 42 mEq/L 38-42\text{ mEq/L} 38 − 42 mEq/L .
Total weak non-volatile acids ( A tot A_{\text{tot}} A tot , primarily albumin and phosphate).
Partial pressure of carbon dioxide ( P a CO 2 Pa\text{CO}_2 P a CO 2 ).
The Pathophysiology of 0.9% Normal Saline
Although historically termed "physiological saline", 0.9 % NaCl 0.9\%\text{ NaCl} 0.9% NaCl is profoundly non-physiological:
It contains 154 mmol/L 154\text{ mmol/L} 154 mmol/L of N a + Na^+ N a + and 154 mmol/L 154\text{ mmol/L} 154 mmol/L of C l − Cl^- C l − , with a S I D = 0 mEq/L SID = 0\text{ mEq/L} S I D = 0 mEq/L .
Infusion of large volumes of saline floods the plasma with supranormal chloride concentrations, drastically reducing the patient's plasma S I D SID S I D . To maintain electrical neutrality, water dissociates into H + H^+ H + ions, and plasma bicarbonate concentration falls precipitously, producing hyperchloremic metabolic acidosis with a normal anion gap.
Renal Hemodynamic Sequelae: Hyperchloremia causes increased chloride delivery to the macula densa in the juxtaglomerular apparatus, triggering tubuloglomerular feedback . This induces profound renal afferent arteriolar vasoconstriction , reducing renal cortical blood flow, decreasing glomerular filtration rate ( G F R GFR GFR ). In the SMART trial (2018), balanced crystalloids modestly reduced major adverse kidney events within 30 days compared with saline, although the larger BaSICS and PLUS trials found no difference in mortality.
Balanced Crystalloids: Hartmann's and Plasmalyte
Balanced crystalloids replace excess chloride with metabolizable organic anions (lactate in Hartmann's; acetate and gluconate in Plasmalyte). These anions are rapidly metabolized (lactate by the liver via gluconeogenesis; acetate and gluconate by peripheral skeletal muscle), generating bicarbonate and maintaining a physiological S I D SID S I D of 28 − 50 mEq/L 28-50\text{ mEq/L} 28 − 50 mEq/L , which largely avoids hyperchloremic acidosis.
Synthetic Colloids: Hydroxyethyl Starches (HES)
Synthetic colloids (hydroxyethyl starches, gelatins, dextrans) were developed to achieve prolonged intravascular volume expansion. However, multi-center randomized controlled trials in critically ill patients (VISEP, 6S, CHEST) established that hydroxyethyl starches (HES) :
Accumulate in the reticuloendothelial system and renal tubular epithelial cells, causing osmotic nephrosis and a significantly increased requirement for renal replacement therapy (dialysis).
Disrupt normal hemostasis by diluting clotting factors, accelerating fibrinolysis, and acquiring von Willebrand syndrome / Factor VIII deficiency.
Trigger severe, intractable pruritus.
Consequently, the US FDA added a boxed warning (2013, strengthened in 2021), and in 2022 the European Medicines Agency recommended suspending HES marketing authorisations across the EU. Natural colloids (5% and 20% human albumin) remain indicated for large-volume paracentesis, severe hypoalbuminemia with septic shock, and select resuscitation contexts where crystalloid volume limits are exceeded.
3. Goal-Directed Hemodynamic Therapy (GDHT) and Dynamic Indices
Goal-Directed Hemodynamic Therapy (GDHT) utilizes continuous stroke volume monitoring to titrate intravenous fluids, vasopressors, and inotropes toward defined physiological targets, optimizing cellular oxygen delivery while avoiding fluid overload. [ THE FRANK-STARLING MECHANISM ]
- Stroke Volume (SV)
- ^
- | Preload-Independent (Plateau)
- | /---------------
- | / (Fluid Non-Responder)
- | /
- | /
- | Preload-Dependent /
- | (Fluid Responder) /
- | /
- | /
- +-------------------------+-------------------------> Preload (EDV)
- Dynamic Indices: SVV and PPV
Static markers of intravascular volume (central venous pressure / CVP, pulmonary capillary wedge pressure / PCWP) fail to predict fluid responsiveness. In contrast, dynamic arterial indices exploit cyclic variations in intrathoracic pressure induced by mechanical ventilation to assess whether the heart is operating on the steep (preload-dependent) or flat (preload-independent) portion of the Frank-Starling curve.
Stroke Volume Variation (SVV) = S V max − S V min ( S V max + S V min ) / 2 × 100 \text{Stroke Volume Variation (SVV)} = \frac{SV_{\max} - SV_{\min}}{(SV_{\max} + SV_{\min}) / 2} \times 100 Stroke Volume Variation (SVV) = ( S V m a x + S V m i n ) /2 S V m a x − S V m i n × 100 Pulse Pressure Variation (PPV) = P P max − P P min ( P P max + P P min ) / 2 × 100 \text{Pulse Pressure Variation (PPV)} = \frac{PP_{\max} - PP_{\min}}{(PP_{\max} + PP_{\min}) / 2} \times 100 Pulse Pressure Variation (PPV) = ( P P m a x + P P m i n ) /2 P P m a x − P P m i n × 100
Threshold Value: An SVV > 12 − 13 % \text{SVV} > 12-13\% SVV > 12 − 13% or a PPV > 13 % \text{PPV} > 13\% PPV > 13% strongly predicts that the patient is fluid-responsive (i.e., administering a fluid bolus of 250 − 500 mL 250-500\text{ mL} 250 − 500 mL of balanced crystalloid will increase stroke volume by > 10 − 15 % >10-15\% > 10 − 15% ).
The 5 Strict Prerequisites for Valid SVV and PPV Interpretation
Dynamic indices are invalid if any of the following 5 criteria are violated:
Regular Sinus Rhythm: Arrhythmias (atrial fibrillation, frequent ectopy) generate beat-to-beat stroke volume variations unrelated to respiration.
Closed Thoracic Cavity: Open thoracotomy or sternotomy abolishes cyclic intrathoracic pressure swings.
Fully Controlled Mechanical Ventilation: Absence of any spontaneous respiratory efforts; spontaneous inspiratory efforts generate negative intrathoracic pressures, producing erratic arterial waveform swings.
Adequate Tidal Volume: Requires a mandatory tidal volume of ≥ 8 mL/kg \ge 8\text{ mL/kg} ≥ 8 mL/kg of ideal body weight (IBW) . Low tidal volume protective ventilation ( 6 mL/kg 6\text{ mL/kg} 6 mL/kg ) generates insufficient intrathoracic pressure swings, causing false-negative readings.
Normal Lung and Chest Wall Compliance: Severe ARDS (reduced pulmonary compliance) or elevated intra-abdominal hypertension impairs transmission of airway pressure to the intrathoracic vasculature.
4. Patient Blood Management (PBM): The Three Pillars
Patient Blood Management (PBM) is an evidence-based, multidisciplinary bundle designed to conserve patient red cell mass and improve outcomes without unnecessary allogeneic blood exposure. [ THREE PILLARS OF PBM ]
- |
- +--------------------------+--------------------------+
- | | |
- [ PILLAR 1 ] [ PILLAR 2 ] [ PILLAR 3 ]
- Optimize Red Cell Minimize Perioperative Optimize Anemia
- Mass & Treat Anemia Blood Loss Tolerance & Triggers
- | | |
- Screen 3-4 wks prior • Meticulous hemostasis • Restrictive triggers
- Oral / IV iron therapy • Tranexamic acid (TXA) (Hb < 70-80 g/L)
- Treat B12 / Folate • Cell salvage • Acute MI: more liberal
- Erythropoiesis agents • Normovolemic hemodilution (Hb < 100 g/L, MINT)
- Pillar 1: Detect and Treat Preoperative Anemia
Anemia is present in up to 30 − 40 % 30-40\% 30 − 40% of elective surgical patients and independently predicts 30-day mortality.
Screen 3 − 4 weeks 3-4\text{ weeks} 3 − 4 weeks prior to surgery: serum ferritin, transferrin saturation (TSAT), renal function.
Iron Deficiency Anemia (IDA): Absolute IDA (ferritin < 30 μ g/L <30\text{ }\mu\text{g/L} < 30 μ g/L ) or functional IDA in chronic inflammation (ferritin < 100 μ g/L <100\text{ }\mu\text{g/L} < 100 μ g/L with TSAT < 20 % \text{TSAT} < 20\% TSAT < 20% ) should be treated aggressively with intravenous iron (e.g., ferric carboxymaltose or ferric derisomaltose); IV iron bypasses hepcidin-mediated intestinal blockade and elevates hemoglobin by 15 − 30 g/L 15-30\text{ g/L} 15 − 30 g/L within 2 − 3 weeks 2-3\text{ weeks} 2 − 3 weeks .
Pillar 2: Minimize Perioperative Blood Loss
Tranexamic Acid (TXA): A synthetic lysine analogue that competitively inhibits plasminogen activation and fibrin binding, halting fibrinolysis. Large randomized trials support its use: CRASH-2 (trauma) and WOMAN (postpartum haemorrhage) showed fewer deaths from bleeding when TXA was given within 3 hours, and POISE-3 (non-cardiac surgery) reduced a composite bleeding outcome, although non-inferiority for cardiovascular complications was not established. Surgical meta-analyses show reduced transfusion without a clear increase in thromboembolic events. Standard dose: 1 g 1\text{ g} 1 g or 10 − 15 mg/kg 10-15\text{ mg/kg} 10 − 15 mg/kg IV at induction, followed by an optional 1 mg/kg/h 1\text{ mg/kg/h} 1 mg/kg/h infusion.
Intraoperative Cell Salvage: Shed blood is aspirated from the surgical field, anticoagulated with heparinized saline, filtered, centrifuged to wash away free hemoglobin, stroma, and debris, and re-suspended in saline to yield packed red cells with a hematocrit of 50 − 70 % 50-70\% 50 − 70% . Contraindications: Contaminated bowel contents in field (unless specialized leukocyte reduction filters are used). Safely utilized in oncological surgery when using leukocyte depletion filtration.
Acute Normovolemic Hemodilution (ANH): Whole blood is collected from the patient immediately prior to surgery into standard citrate bags and replaced with crystalloid or colloid to maintain euvolemia. Blood lost during surgery has a lower hematocrit; the stored autologous blood (containing active platelets and clotting factors) is re-infused post-hemostasis.
Pillar 3: Optimize Physiological Tolerance to Anemia and Restrictive Triggers
Restrictive Transfusion Strategy: Large-scale multicenter trials (TRICC, FOCUS, TRISS) confirm that a restrictive transfusion threshold of H b < 70 − 80 g/L Hb < 70-80\text{ g/L} H b < 70 − 80 g/L ( 7.0 − 8.0 g/dL 7.0-8.0\text{ g/dL} 7.0 − 8.0 g/dL ) is non-inferior or superior to a liberal threshold ( H b < 100 g/L Hb < 100\text{ g/L} H b < 100 g/L ) in stable critically ill and general surgical patients, significantly lowering nosocomial infections, transfusion-related circulatory overload (TACO), and transfusion-related acute lung injury (TRALI).
Acute Myocardial Infarction Exception: In the MINT trial (2023; 3,504 patients with acute myocardial infarction and H b < 100 g/L Hb < 100\text{ g/L} H b < 100 g/L ), a restrictive strategy (transfusion permitted below 80 g/L 80\text{ g/L} 80 g/L ) was followed by death or reinfarction at 30 days in 16.9 % 16.9\% 16.9% versus 14.5 % 14.5\% 14.5% with a liberal strategy (transfusion below 100 g/L 100\text{ g/L} 100 g/L ) (risk ratio 1.15, p = 0.07 p = 0.07 p = 0.07 ). Many clinicians therefore use a more liberal threshold, around H b < 100 g/L Hb < 100\text{ g/L} H b < 100 g/L , in acute myocardial infarction.
5. Viscoelastic Hemostatic Testing: ROTEM and TEG
Standard laboratory coagulation tests (PT/INR, aPTT, fibrinogen) are performed on cell-free, centrifuged plasma at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C and require 45 − 60 minutes 45-60\text{ minutes} 45 − 60 minutes , reflecting only initial thrombin generation. In contrast, viscoelastic tests — Rotational Thromboelastometry (ROTEM) and Thromboelastography (TEG) —provide point-of-care, real-time assessment of the entire clotting process in whole blood, evaluating platelet-fibrin interactions, clot elasticity, and hyperfibrinolysis within 10 − 15 minutes 10-15\text{ minutes} 10 − 15 minutes . [ ROTEM TRACING PARAMETERS ]
- CT
- [<--->]
- | |
- ---+-----+-------------------
- | / \ |
- | / \ | MCF
- | / \---------------|---
- | / |
- ---+------------------------+-------------------
- | \ /----------------|---
- | \ / |
- | \ / |
- ---+----+-------------------
- [<->]
- CFT
- ROTEM Assays
EXTEM: Extrinsic pathway triggered by tissue factor; assesses factors VII, X, II, fibrinogen, and platelets.
INTEM: Intrinsic pathway triggered by ellagic acid; assesses factors XII, XI, IX, VIII, X, II, fibrinogen, and platelets.
FIBTEM: Extrinsic pathway (tissue factor) plus cytochalasin D , which selectively inhibits platelet cytoskeleton activation. Because platelets cannot contribute to clot firmness, the FIBTEM tracing isolates the pure contribution of fibrinogen to clot strength.
APTEM: Extrinsic pathway with added aprotinin/tranexamic acid , which inhibits fibrinolysis in vitro; confirming hyperfibrinolysis if abnormal lysis in EXTEM normalizes in APTEM.
HEPTEM: Intrinsic pathway with heparinase ; eliminates heparin effect to detect true factor deficiency.
Viscoelastic Parameters, Interpretation, and Targeted Therapy
Clinical Phase ROTEM Parameter TEG Parameter Physiological Process Pathological State Targeted Clinical Intervention
Clot Initiation CT (Clotting Time, sec) R time (Reaction time, min) Thrombin generation and initial fibrin formation Coagulation factor deficiency or heparin effect Fresh Frozen Plasma (FFP) ( 15 mL/kg 15\text{ mL/kg} 15 mL/kg ) or Prothrombin Complex Concentrate (PCC) ( 25 IU/kg 25\text{ IU/kg} 25 IU/kg )
Clot Kinetics CFT (sec) & α \alpha α -angle K time & α \alpha α -angle Speed of fibrin cross-linking and polymerization Severe fibrinogen deficiency or platelet dysfunction Fibrinogen Concentrate ( 30 − 60 mg/kg 30-60\text{ mg/kg} 30 − 60 mg/kg ) or Cryoprecipitate
Clot Strength MCF (Maximum Clot Firmness, mm) MA (Maximum Amplitude, mm) Maximum mechanical strength of clot (platelets 80 % 80\% 80% , fibrinogen 20 % 20\% 20% ) • Low FIBTEM MCF: Fibrinogen deficiency; Normal FIBTEM with low EXTEM: Thrombocytopenia • If FIBTEM MCF < 10 mm \text{FIBTEM MCF} < 10\text{ mm} FIBTEM MCF < 10 mm : Fibrinogen Concentrate ; If EXTEM MCF < 45 mm \text{EXTEM MCF} < 45\text{ mm} EXTEM MCF < 45 mm and FIBTEM ≥ 12 mm \text{FIBTEM} \ge 12\text{ mm} FIBTEM ≥ 12 mm : Platelets
Clot Breakdown ML (Maximum Lysis, > 15 % >15\% > 15% ) LY30 (Lysis at 30 min, > 3 % >3\% > 3% ) Premature clot breakdown by plasmin Hyperfibrinolysis Tranexamic Acid (TXA) ( 1 − 2 g 1-2\text{ g} 1 − 2 g IV)